文献速递核素与放射性配体治疗肿瘤 PET/CT

225Ac-PSMA-617治疗177Lu-PSMA难治性转移性去势抵抗性前列腺癌的临床研究分析

Clinical research analysis of [225Ac]Ac-PSMA-617 therapy for [177Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-09

72.22%患者PSA任何程度下降,55.56%下降>50%,38.89%下降>80%,疾病控制率38.89%;中位无进展生存期4个月,中位总生存期17个月;毒性多为I~III级,贫血最常见,全部患者出现不同程度口干。

要点

  • 225Ac-PSMA-617对177Lu-PSMA难治性mCRPC有显著抗肿瘤活性且毒性较低。
  • 72.22%患者PSA任何程度下降,55.56%下降>50%,38.89%下降>80%。
  • 既往177Lu-PSMA≥2周期或≥3周期者中位PFS显著更长。

核心结论

  • 对177Lu-PSMA治疗不耐受或无应答的mCRPC患者,225Ac-PSMA-617显示出显著且安全的抗肿瘤效果,治疗相关毒性相对较低。

研究设计与样本

  • 治疗后第2、4、8周检测PSA和血细胞计数,基线分期及第2个月随访采用68Ga-PSMA-11 PET/CT,安全性按CTCAE v5.0评估。

主要发现

  • 72.22%患者PSA任何程度下降,55.56%下降>50%,38.89%下降>80%;按PSMA PET进展标准,38.89%患者达到疾病控制。
  • 225Ac-PSMA-617治疗后中位无进展生存期4个月,中位总生存期17个月。
  • PSA任何下降、PSA下降≥50%、既往至少2周期和至少3周期177Lu-PSMA治疗均与PFS显著相关。
  • 接受≥2周期177Lu-PSMA者中位PFS为4.8个月(95%CI:3.7-5.9),仅1周期者为2.4个月(95%CI:1.6-3.2)。
  • 接受≥3周期177Lu-PSMA者中位PFS为5.3个月(95%CI:4.0-6.5),<3周期者为3个月(95%CI:2.0-4.0)。

关键数值与推荐

  • 每周期225Ac-PSMA-617平均活度6.1 MBq。
  • PSA任何程度下降者占72.22%,下降>50%者占55.56%,下降>80%者占38.89%。
  • 疾病控制率38.89%,中位PFS 4个月,中位OS 17个月。
  • ≥2周期177Lu-PSMA者中位PFS 4.8个月(95%CI:3.7-5.9),仅1周期者2.4个月(95%CI:1.6-3.2)。
  • ≥3周期177Lu-PSMA者中位PFS 5.3个月(95%CI:4.0-6.5),<3周期者3个月(95%CI:2.0-4.0)。

临床怎么用

  • 对于177Lu-PSMA治疗不耐受或无应答的mCRPC患者,可考虑225Ac-PSMA-617作为后续治疗选择。
  • 治疗期间应监测PSA和血细胞计数,重点关注贫血和口干等毒性反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this evaluation was to identify the safety and efficacy for [225Ac]Ac-labeled prostate-specific membrane antigen-617 therapy in a retrospectively analyzed group of patients after [177Lu]Lu-PSMA therapy. METHODS: Metastatic castration-resistant prostate cancer patients after [177Lu]Lu-PSMA were selected for treatment with 1 ~ 5 cycles of [225Ac]Ac-PSMA-617. Prostate-specific antigen and blood cell count were measured at the 2nd, 4th, and 8th week after treatment. [68Ga]Ga-PSMA-11 PET/CT was used for baseline staging and imaging follow-up at the 2nd month. Safety was assessed according to the Common Terminology Criteria for Adverse Events version 5.0. RESULTS: Eighteen patients were treated per protocol with a mean activity of 6.1 MBq in each cycle. 72.22% had a PSA decline at any degree, 55.56% had a PSA decline at more than 50%, and 38.89% had a PSA decline at more than 80%. According to PSMA PET progression criteria, disease control was achieved in 38.89% of the patients. The median progression-free survival under [225Ac]Ac-PSMA-617 after [177Lu]Lu-PSMA therapy was 4 mo; the median overall survival was 17 mo. Any decline in PSA, a decline in PSA of ≥ 50%, prior treatment with at least 2 cycles and at least 3 cycles of [177Lu]Lu-PSMA were all significantly associated with PFS. The median PFS was significantly longer for patients receiving ≥ 2 cycles of [177Lu]Lu-PSMA therapy (4.8 mo, 95% CI: 3.7-5.9) compared to those receiving only 1 cycle (2.4 mo, 95% CI: 1.6-3.2). Median PFS was 5.3 mo (95% CI: 4.0-6.5) with ≥ 3 cycles of [177Lu]Lu-PSMA therapy, compared to 3 mo (95% CI: 2.0-4.0) in those receiving < 3 cycles.Toxic reactions and adverse effects were mostly grade I ~ III and anemia is the most common hematological toxic reaction. The change in hemoglobin levels before and after [225Ac]Ac-PSMA treatment was statistically significant (p = 0.006). All patients experienced xerostomia to varying degrees. CONCLUSION: For metastatic castration-resistant prostate cancer patients intolerant or unresponsive to [177Lu]Lu-PSMA treatment, [225Ac]Ac-PSMA-617 demonstrated significant and safe antitumor effects with relatively low treatment-related toxicity.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rao Z, Ma J, Jiangchu Y, et al. Clinical research analysis of [225Ac]Ac-PSMA-617 therapy for [177Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 41656423. doi:10.1007/s00259-026-07778-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。